#China #Shanghai #HER2-positive #DualityBio #Trastuzumab

DualityBio's Advancements in Breast Cancer Treatment

Duality Biotherapeutics, often referred to as DualityBio, has made significant strides in the fight against breast cancer. The company recently announced that the China National Medical Products Administration (NMPA) has accepted their application for the investigational drug Trastuzumab Pamirtecan, commonly known as T-Pam, for review. This therapy aims to provide new hope for patients suffering from unresectable or metastatic HER2-positive breast cancer.

The drug is an antibody-drug conjugate (ADC) designed to target the HE2 protein on cancer cells, which is associated with aggressive tumor growth. As breast cancer remains a major health concern in China, with over 350,000 new cases reported each year, this announcement marks a crucial milestone in providing treatment options for patients battling this prevalent disease.

Positive Clinical Trials: Evidence of Efficacy

The application for Trastuzumab Pamirtecan was bolstered by positive interim results from a pivotal Phase III clinical trial (Study DB-1303-O-3001). Conducted in multiple centers across China, this randomized and controlled study evaluated the effectiveness and safety of T-Pam against the existing treatment, Trastuzumab Emtansin (T-DM1), in patients who previously received standard therapies, including Trastuzumab and chemotherapy.

Dr. Hua Mu, the global medical director of DualityBio, expressed enthusiasm about the findings, highlighting that the trial reached its primary endpoint during a pre-specified interim analysis. This showed a statistically significant improvement in progression-free survival (PFS) for patients treated with Trastuzumab Pamirtecan compared to T-DM1, indicating a promising alternative for patients.

Collaborations and Future Endeavors

In addition to the drug's clinical significance, DualityBio is collaborating with 3SBio to facilitate the commercialization of Trastuzumab Pamirtecan across Mainland China, Hong Kong, and Macau. Furthermore, the company has established strategic partnerships with BioNTech to advance the global development of this therapy. Such alliances empower DualityBio to accelerate the product's market entry while maximizing its clinical value for patients around the world.

Dr. Mu emphasized the importance of these partnerships, stating, "DB-1303/T-Pam is a globally pioneered new drug with strong strategic partners in both local and global markets. We aim to work closely to streamline the product's approval process and provide diverse treatment options to breast cancer patients.”

The Potential Impact of T-Pam

Trastuzumab Pamirtecan, apart from targeting HER2-positive tumors, has also demonstrated antitumor activity across various solid tumor models. It holds promise not just for breast cancer but potentially for endometrial carcinoma and other advanced solid tumors. The advancements from clinical trials and the drug's unique mechanism offer new avenues for treatment, especially for patients who have limited options due to disease progression or previous treatment failures.

Besides the accepted application by the NMPA, the investigational drug has received Fast-Track designation and Breakthrough Therapy designation from the U.S. Food and Drug Administration, highlighting its potential impact on facilitating patient care and expediting its review process in the United States.

DualityBio's Commitment to Cancer Therapy

DualityBio stands out as a clinical-stage biotech company dedicated to discovering and developing next-generation ADCs for both cancer and autoimmune conditions. Their commitment is further reflected in its state-of-the-art technology platforms and extensive clinical trials spanning multiple countries, with over 3,200 patients enrolled in several clinical studies. With its innovative approach and growing pipeline, DualityBio plays a vital role in advancing cancer therapies.

As T-Pam progresses through the regulatory channels in China and internationally, its success could redefine treatment trajectories for patients battling HER2-positive breast cancer and set a new standard in the therapeutic landscape. For insight into DualityBio's journey and commitment to innovation, visit DualityBio's official website.